HGH vs MK-677: Growth-Hormone Axis Comparison | Peptide Intel Hub

HGH (recombinant somatropin) is a 191-amino-acid recombinant protein identical to native human growth hormone. It acts directly at the growth-hormone receptor as the endpoint of the growth-hormone axis, bypassing the entire hypothalamic-pituitary secretagogue cascade.

MK-677 (ibutamoren) is a non-peptide small molecule that acts as an orally active agonist at the growth-hormone-secretagogue receptor. It drives the endogenous growth-hormone axis to release GH through the natural pituitary pathway — producing an endogenous, pulsatile GH signal rather than an exogenous flat signal.

HGH acts at the growth-hormone receptor directly and drives IGF-1 production through the natural hepatic-axis downstream signalling. The pharmacological signature is a direct, dose-dependent exogenous GH signal.

MK-677 acts at the ghrelin receptor and drives endogenous GH release from the pituitary. The signature is a sustained but still pulsatile GH release pattern, with the natural axis preserved.

HGH has a short pharmacokinetic half-life (approximately 2–3 hours) and is typically administered by subcutaneous research injection at daily or sub-daily cadences.

MK-677 has a reported half-life of approximately 24 hours, is dosed orally once daily in published research, and produces a sustained ghrelin-axis stimulus.

HGH is used in research protocols requiring direct exogenous growth-hormone exposure — GH-receptor pharmacology, receptor-signalling studies and any design where controlling the GH signal directly is the requirement.

MK-677 is used in research protocols requiring sustained endogenous GH-axis activation with the natural pituitary axis intact — chronic-exposure metabolic, body-composition or sleep-architecture research models where preserving the endogenous pulsatile release is part of the design.

Both HGH (Somatropin) and MK-677 should only be sourced from suppliers that use independent third-party verification — Janoshik Analytical is the default verifier, with orthogonal independent laboratories used when batch chemistry calls for confirmation by a second method. Minimum release specification is ≥99.0% HPLC main-peak purity with matching mass-spectrometry molecular weight and water content within the published specification for the compound.

Batch COAs for both compounds should be published by the supplier so a researcher can audit the analytical detail. The /trust/how-to-read-a-coa reference walks through every field on a modern COA.

HGH ships as a lyophilised recombinant protein; hold at 2–8 °C, avoid freeze-thaw cycling, and reconstitute with bacteriostatic water for a refrigerated in-use window. MK-677 ships as a solid or oral-solution research kit; storage conditions are cool and dry, protected from light. HGH is substantially more sensitive to handling than MK-677.

Aliquot before any freeze. The single most common cause of measurable potency loss in research peptides is repeat freeze-thaw cycling — both HGH (Somatropin) and MK-677 benefit from single-thaw aliquot workflows. Vortex gently, never shake aggressively, and keep reconstituted vials away from direct light. The /research/compound-storage-guide reference covers the per-compound stability windows in detail.

Researchers choose HGH when the protocol requires direct exogenous GH-receptor activation or a controlled exogenous GH signal for pharmacology or receptor studies. Researchers choose MK-677 when the protocol requires sustained oral endogenous GH-axis activation, when preserving the natural pituitary axis is part of the design, or when a chronic-exposure oral research tool is preferable to an injectable exogenous protein.

For multi-compound comparator studies, reputable suppliers can often reserve matched-batch inventory of both HGH (Somatropin) and MK-677 against a project timeline so the experimental panel is sourced under a single analytical specification window.

Somatropin, a recombinant human growth hormone (rhGH), has been a cornerstone in treating growth hormone deficiency (GHD) in both pediatric and adult patients (PMID 23662811). Its availability revolutionized the treatment of short stature stemming from GHD and is also used in other conditions not fitting the classic GHD definition, such as intrauterine growth restriction and Turner syndrome (PMID 11817985). Early treatment of GHD with somatropin aims to promote linear growth and allow children to reach their genetic potential (PMID 23662811, PMID 37906847).

Clinical trials have demonstrated somatropin's efficacy in pediatric populations. For instance, in a retrospective study of 50 Mexican children with isolated and severe GHD, somatropin treatment normalized linear growth and enabled most to achieve their genetic height potential (PMID 37906847). The highest growth velocity was observed during the first year of treatment (PMID 37906847). The Kabi/Pfizer International Growth Database (KIGS), a large international database of rhGH-treated children from 1987-2012, further supports that rhGH is safe and increases short-term height gain and adult height across GHD and non-GHD conditions (PMID 36102184). For example, median gains in near-adult height-SD scores were 1.79 for boys with idiopathic GHD and 2.07 for girls with idiopathic GHD (PMID 36102184).

Newer formulations of somatropin or related long-acting rhGHs are continually being developed. Somatrogon, a long-acting rhGH, showed noninferiority to once-daily somatropin in a 12-month, phase 3 study involving 228 prepubertal children with GHD (PMID 35405011). Annualized height velocity at month 12 was 10.10 cm/year for somatrogon-treated subjects and 9.78 cm/year for somatropin-treated subjects, with similar safety and tolerability profiles (PMID 35405011). Similarly, lonapegsomatropin, an investigational long-acting once-weekly prodrug, demonstrated both noninferiority and superiority over daily somatropin in a 52-week Phase 3 trial for treatment-naïve children with GHD (PMID 34272849).

In adults, somatropin replacement therapy offers beneficial effects for individuals with GHD, a complex clinical condition (PMID 35241041, PMID 15871547). Long-term administration has been shown to improve body composition, muscle strength, quality of life, bone mass and density, and lipoprotein patterns (PMID 15871547). It can also restore normal body composition, improve cardiac function, and normalize cardiovascular risk factors like low-density lipoprotein cholesterol and C-reactive protein (PMID 23662811). However, the extent to which somatropin therapy reduces cardiovascular morbidity and mortality in GH-deficient adults still requires determination (PMID 15871547).

The impact of somatropin on quality of life (QOL) in GH-deficient adults is a recognized area of research (PMID 16879003). GH and insulin-like growth factor-1 (IGF-I) can affect mood parameters through their actions in specific brain areas or by influencing dopamine turnover (PMID 16879003). Substantial evidence suggests that somatropin treatment improves QOL in GH-deficient patients, although the variety of instruments used to measure QOL can make interpretation challenging (PMID 16879003). A meta-analysis comparing somatropin treatment effects to baseline and placebo showed improved mood status in GH-deficient patients at 3, 6, and 12 months, though the median 6-month treatment period did not improve mood status more than placebo (PMID 16879003).

Beyond physical and psychological well-being, somatropin may also influence cognitive function in adults. Both GH and IGF-I have receptors in brain areas linked to cognitive function (PMID 16677058). While data are limited, there is a suggestion that GHD can lead to specific cognitive changes, particularly attentional deficits and altered processing speed (PMID 16677058). However, the precise underlying mechanisms and the effects of somatropin treatment on cognitive function in GHD remain unclear (PMID 16677058). Careful documentation of metabolic effects, including lipid profile, bone mineral density, and muscle mass, is crucial, especially with higher doses or in susceptible populations (PMID 11817985).

While generally considered safe, somatropin therapy has known adverse reactions. These include intracranial hypertension, fluid retention, and glucose intolerance (PMID 23662811). In children, there is a possibility of worsening scoliosis and slipped capital femoral epiphysis (PMID 23662811). An increased risk for intracranial tumors has been reported in teenagers and young adults who received radiation to the head as children for a first neoplasm (PMID 23662811).

Data from the KIGS database, representing a large real-world cohort of rhGH-treated children, provide further insights into safety (PMID 36102184). In this cohort of over 83,000 patients, serious adverse events (SAEs) occurred in 3.7% of patients, and death in 0.4% (PMID 36102184). The most common SAEs identified were recurrence of craniopharyngioma (n=151), neoplasm (n=99), cancer (n=91), and scoliosis (n=91) (PMID 36102184).

Given the chronic nature of GHD treatment, particularly in adults, meticulous monitoring is mandatory (PMID 15871547). This includes thorough long-term monitoring of glucose metabolism, cardiovascular measurements, and any underlying pituitary disease (PMID 15871547). In children, continuous monitoring, long-term follow-up to near-adult height, and well-defined treatment endpoints are needed (PMID 11817985).

Ibutamoren, also known as MK-677, is an orally active nonpeptide mimic of GH-releasing peptide, functioning as a growth hormone secretagogue (GHS) (PMID 9467534, PMID 28400207). GHSs promote the pulsatile release of GH, which is subject to negative feedback mechanisms, potentially preventing supra-therapeutic GH levels and associated sequelae (PMID 28400207). This contrasts with exogenous GH administration, where impaired regulatory feedback can be a concern (PMID 28400207).

Ibutamoren has shown the ability to stimulate GH and IGF-I levels. In a human study with healthy volunteers on a calorically restricted diet, MK-677 (25 mg once daily for 7 days) produced a peak GH response of 55.9 ± 31.7 micrograms/L after a single dose and 22.6 ± 9.3 micrograms/L after a week of dosing (PMID 9467534). Mean IGF-I concentration also increased significantly during MK-677 treatment to 264 ± 31 ng/mL, compared to 188 ± 19 ng/mL with placebo (human evidence, PMID 9467534). Another human study on elderly adults administered MK-677 (10 mg or 25 mg daily) for 2 weeks showed a significant increase in serum IGF-I levels by 55-94% (PMID 10404019).

The potential applications of GHSs, including ibutamoren, are under investigation. Available human studies indicate that GHSs might improve growth velocity in children, stimulate appetite, improve lean mass in wasting states and in obese individuals, decrease bone turnover, increase fat-free mass, and improve sleep (PMID 28400207). For instance, in healthy elderly subjects, MK-677 increased mean serum osteocalcin by 8% and serum IGF-I levels by 55-94% after 2 weeks of treatment (human evidence, PMID 10404019). The biological effects were further studied in functionally impaired elderly subjects over 9 weeks, showing increases in mean serum osteocalcin by 29.4%, bone-specific alkaline phosphatase by 10.4%, and urinary N-telopeptide cross-links by 22.6% (human evidence, PMID 10404019).

Despite some promising biological effects on hormone levels and bone markers, robust human clinical evidence for the broad efficacy of ibutamoren (MK-677) remains limited. A scoping review noted that while animal models showed promising but variable effects on musculoskeletal tissue healing for several peptides including MK-677, human clinical studies were scarce, often lacking robust controls or rigorous designs (PMID 42578445). For MK-677, human data showed modest improvements at best for metabolic bone health and degenerative knee pain (PMID 42578445).

In a phase IIb study investigating MK-677 (25 mg/day) in 123 elderly hip fracture patients, an increase in plasma IGF-1 levels was observed (51.4 ng/ml compared to placebo), but this was not paralleled by improvement in most functional performance measures (human evidence, PMID 21067829). While gait speed increased by a 0.7-score difference and the MK-677 group experienced fewer falls compared to placebo, the study was terminated early due to a safety signal (human evidence, PMID 21067829).

Significant safety concerns have been identified with ibutamoren use. The phase IIb study in hip fracture patients was terminated early due to a safety signal of congestive heart failure in a limited number of patients (human evidence, PMID 21067829). Furthermore, a scoping review explicitly stated that MK-677 was associated with significant risks, including congestive heart failure and metabolic dysfunction such as insulin resistance (PMID 42578445). A case report on a 25-year-old male co-administering LGD-4033 and MK-677 daily for 5 weeks noted negative impacts on bone mineral content, serum lipids (e.g., cholesterol, triglycerides, LDL-C increased; HDL-C decreased), and liver enzymes (e.g., AST, ALT increased), along with changes in testosterone levels (human evidence, PMID 36303408).

Ibutamoren's metabolic profile has been characterized, particularly due to its potential for abuse as a performance-enhancing agent in sports (PMID 34542924, PMID 35716382). In vitro studies using equine liver microsomes identified 32 metabolites, including 20 phase I and 12 phase II metabolites (in-vitro animal evidence, PMID 34542924). Key findings included ibutamoren's susceptibility to oxidation, resulting in hydroxylated metabolites, and the detection of glucuronic acid conjugates (in-vitro animal evidence, PMID 34542924).

Further studies in thoroughbred horses after oral administration of ibutamoren identified 22 metabolites (17 phase I and 5 phase II), with oxidation leading to mono- and dihydroxylated metabolites (animal evidence, PMID 35716382). Dissociated side chains and hydrogenated metabolites were also detected (animal evidence, PMID 35716382). These major metabolites, along with ibutamoren itself, can be detected for several days after a single dose, aiding in doping control (animal evidence, PMID 35716382). For example, major metabolites were detectable up to 96 hours and ibutamoren itself up to 72 hours after a single dose in horses (animal evidence, PMID 35716382).

Methods for detecting ibutamoren in humans, particularly for performance enhancement, have also been established. A study on a male volunteer who took a single 10 mg dose of ibutamoren showed a positive hair test result of 1.3 pg/mg (segment 0 to 1 cm) after 4 weeks (human evidence, PMID 40882886). In another human case, a subject who took 60 capsules of 10 mg ibutamoren over 90 days had 224 pg/mg in their hair (0 to 4 cm segment) after 4 weeks of discontinuation, highlighting its incorporation into hair (human evidence, PMID 40882886). These data are crucial for interpreting hair test results and detecting illegal use of ibutamoren (PMID 40882886).

• Efficacy and Safety of Weekly Somatrogon vs Daily Somatropin in Children With Growth Hormone Deficiency: A Phase 3 Study. — The Journal of clinical endocrinology and metabolism (2022). PMID 35405011
• Somatropin therapy in italian adults with growth hormone deficiency. — BMC endocrine disorders (2022). PMID 35241041
• Weekly Lonapegsomatropin in Treatment-Naïve Children With Growth Hormone Deficiency: The Phase 3 heiGHt Trial. — The Journal of clinical endocrinology and metabolism (2021). PMID 34272849
• Safety and Efficacy of Pediatric Growth Hormone Therapy: Results From the Full KIGS Cohort. — The Journal of clinical endocrinology and metabolism (2022). PMID 36102184
• Growth hormone therapy with norditropin ( somatropin ) in growth hormone deficiency. — Expert opinion on biological therapy (2013). PMID 23662811
• Long-term efficacy and safety of somatropin for adult growth hormone deficiency. — Treatments in endocrinology (2003). PMID 15871547
• [Somatropin and final height in Mexican paediatric population with growth hormone deficiency]. — Andes pediatrica : revista Chilena de pediatria (2022). PMID 37906847
• Impaired quality of life in hypopituitary adults with growth hormone deficiency : can somatropin replacement therapy help? — Treatments in endocrinology (2006). PMID 16879003
• Somatropin therapy and cognitive function in adults with growth hormone deficiency : a critical review. — Treatments in endocrinology (2006). PMID 16677058
• The use of somatropin (recombinant growth hormone) in children of short stature. — Paediatric drugs (2002). PMID 11817985
• MK-677, an orally active growth hormone secretagogue, reverses diet-induced catabolism. — The Journal of clinical endocrinology and metabolism (1998). PMID 9467534
• Peptide Supplements and Their Therapeutic Applications in Sports Medicine. — The American journal of sports medicine (2026). PMID 42578445
• LGD-4033 and MK-677 use impacts body composition, circulating biomarkers, and skeletal muscle androgenic hormone and receptor content: A case report. — Experimental physiology (2022). PMID 36303408
• Knowing the minimal detectable dose can facilitate the interpretation of a hair test result: II. Case example with ibutamoren (MK-677), a growth hormone secretagogue. — Clinica chimica acta; international journal of clinical chemistry (2026). PMID 40882886
• Characterization of equine liver microsome-generated metabolites of growth hormone secretagogue small molecule ibutamoren. — Rapid communications in mass spectrometry : RCM (2021). PMID 34542924
• Characterization of growth hormone secretagogue small molecule ibutamoren (MK-0677) and its possible metabolites in thoroughbred horses for doping control. — Rapid communications in mass spectrometry : RCM (2022). PMID 35716382
• The Safety and Efficacy of Growth Hormone Secretagogues. — Sexual medicine reviews (2018). PMID 28400207
• MK-0677 (ibutamoren mesylate) for the treatment of patients recovering from hip fracture: a multicenter, randomized, placebo-controlled phase IIb study. — Archives of gerontology and geriatrics (2011). PMID 21067829
• Oral administration of the growth hormone secretagogue MK-677 increases markers of bone turnover in healthy and functionally impaired elderly adults. The MK-677 Study Group. — Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research (1999). PMID 10404019

Both HGH (Somatropin) and MK-677 are supplied strictly for in-vitro and preclinical research use. They are not medicines, are not approved for human consumption in Spain, the United Kingdom, the European Union or the United States, and are not dispensed against a prescription. The research-use declaration ships with every package alongside the independent third-party COA.

Comparison pages on Peptide Intel Hub exist for laboratory-research reference. Nothing on this page constitutes a recommendation for human use of either compound.